Malnutrition in patients undergoing hematopoietic SCT is known as a risk factor for adverse effects and is directly or indirectly responsible for excess mortality and morbidity. We designed the present study to evaluate the effects of individualized parenteral nutrition (PN) and compare the present method to the conventional PN. Individualized PN based on the Harris À Benedict equation was administered to 30 patients after hematopoietic SCT and was compared with an age, gender and disease matched group of patients who underwent hematopoietic SCT with conventional PN. These two groups were compared on clinical, hematological, nutritional outcomes. Comparing duration of hospital stay (P valueo0.0001), infection (P value ¼ 0.01), time to platelet engraftment (P value ¼ 0.02), units of packed cell transfusion (P value ¼ 0.006) and decrease in body weight (P value ¼ 0.004) showed significant differences between the two groups. In conclusion, the use of individualized PN seems more beneficial than conventional PN.
INTRODUCTION
Hematopoietic SCT is a complicated technique comprised of the administration of high-dose chemotherapy followed by i.v. infusion of hemopoietic stem cells to reinstitute marrow function. Hematopoietic SCT is used in the treatment of hematologic malignancies, solid tumors and autoimmune disorders. 1 During the hematopoietic SCT procedure, patients usually develop nausea, anorexia, mucositis, diarrhea and decreased tolerance to oral nutrition and medications. Moreover, hematopoietic SCT recipients are susceptible to infection due to neutropenia, chemotherapy side effects on gastrointestinal mucosa and skin, central vein catheters and etc. 2 These effects may restrict sufficient oral intake for a long time, which renders hematopoietic SCT recipients prone to malnutrition and weight loss during the hematopoietic SCT procedure. 3 Malnutrition which is associated with poor quality of life, susceptibility to infection and socioeconomic problems reduces the cost-benefit and risk-benefit ratios of anticancer treatments, increases the duration of hospital stay and is directly or indirectly responsible for excess mortality among cancer patients. 3 So monitoring of nutritional status and nutritional intake is a fundamental part of supportive care in hematopoietic SCT recipients, 4 which made nutrition one of the serious challenges in the post-transplant period. 5 During the past two decades, parenteral nutrition (PN) has moved from being a simple supportive care to an adjunctive therapy in hematopoietic SCT recipients. 6, 7 It is shown that PN improves hematological and immunological function in some hematopoietic SCT recipients and it has been used extensively for these patients to maintain or restore lean body mass and to accelerate engraftment, although patients can recover hematologic and immunologic function without the requirement of PN. 2, 5, [8] [9] [10] Advantages and disadvantages of PN support are still being discussed. 1 Furthermore, PN is an expensive therapeutic modality that is correlated with risks such as infection, injury during catheter replacement, volume overload, metabolic derangements and venous thrombosis. 9 So the benefits of PN should be weighed against its risks especially in patients undergoing hematopoietic SCT. We therefore designed the present study to evaluate the efficacy and safety of individualized PN, based on nutritional requirements of every patient, who received autologous hematopoietic SCT and compare the present method with the conventional PN administered to a matched group of patients in Taleghani BMT center.
PATIENTS AND METHODS Patients
From September 2009 to December 2010, 30 patients with hematologic malignancies who underwent autologous hematopoietic SCT in Taleghani BMT center of Tehran-Iraincluded in the study (group A). These patients (group A), were pair-matched with another group of 30 patients (group B), with the same gender, age and disease, who received conventional PN admitted from September 2007 to August 2009 at Taleghani hospital. All patients underwent stem cell mobilization with G-CSF (5 mg/kg twice daily 1 i.v.infusion rounded to 300 mg) for 5-6 days.PBSC collection then was performed by a continuous-flow blood cell separator (cobe spectra, Terumo BCT, Inc, Lakewood, CO, USA). Patients received conditioning regimens based on type of disease(represented in Table 1 ) followed by infusion of previously harvested autologous PBSC. G-CSF 5 mcg/kg/day i.v. infusion during 20 min was then started on day þ 1 until WBC engraftment.
Calculation of PN Dose
Patients in the both groups received oral low-bacterial diet with nearly 1800 kcal/day for females and 2200 kcal/day for males before initiation of PN. Oral intake of patients in group A was assessed daily and the criterion for starting of PN was impossibility of oral feeding to meet 60% or more of the daily energy requirements. In the patients in group B, initiation of PN was based on physician decision and patient nutritional status. Individualized PN was administered to group A after hematopoietic SCT during 24 h. The calculation of basal energy expenditure (BEE) was based on the Harris À Benedict equation. The daily requirement energy for patients undergoing hematopoietic SCT is 130-150% of BEE, which was calculated for every patient individually according to body mass index. 5 The required amount of amino acid was 1.5-2 g/kg/day, and the rest of the daily energy requirement consisted of lipid 30-40% and dextrose 60-70%. PN was the same for all the patients in group B and was consisted of amino acid 10%, 500 mL daily, intralipid emulsion 10%, 500 mL every other day and dextrose water 5%. 2000 mL daily. Group A received total energy expenditure equal to 32.01 ± 6.94 kcal/kg/day and 1.43 ± 0.25 g/kg/day amino acid from amino acid 10% (Aminoplasmal-10% E, B. Braun Melsungen AG,Germany), 0.74 ± 0.17 g/kg/day lipid from intra lipid emulsion 10% (Lipovenoes PLR, Fresenius Kabi, Germany) and 4.79±1.31 g/kg/day dextrose from dextrose. The patients in this group (group B) received total energy expenditure equal to 12.31 ± 2.22 kcal/kg/ day and 0.70 ± 0.13 g/kg/day of amino acid from daily administration of amino acid 10% (Aminoplasmal-10% E, B. Braun Melsungen AG, Germany), 0.35 ± 0.06 g/kg/day lipid from every other day administration of intralipid emulsion 10% (Lipovenoes PLR,Fresenius Kabi, Germany) and 1.69±0.30 g/ kg/day of dextrose from daily dextrose. Table 2 summarizes the comparison of two groups daily parenteral intakes. Vitamins and minerals, according to available forms in Iran were added to PN solutions that are represented in Table 3 . Patients received low-bacterial diet which was allowed as needed for both groups. Parenteral solutions were given via a central vein catheter. When ANC was more than 500 /mL for three consecutive days and the patient could cover most of the daily energy requirements orally, 11, 12 PN was withdrawed by decision of hematologist, clinical pharmacist and clinical dietician.
By convention, duration before PN administration was designated 'time 1', during PN administration'time 2' and duration between discontinuation of PN to discharge 'Time 3'.These two groups were compared on clinical (duration of hospital stay, fever, infection and mortality), nutritional (body weight, serum proteins, and days of PN) and hematologic outcomes (WBC, platelet engraftment, packed cell and platelet transfusions). Anthropometric data concerning the weight of the patients were collected daily. Weights were measured using an accurate electronic scale. Serum levels of albumin and total protein were measured weekly. Complete blood cell counts were obtained daily. The day of engraftment for WBC was defined as the day on which ANC was greater than 500 per mL for three consecutive days and the day of engraftment for platelet was defined as the day on which platelet counts reached greater than 20 000 per mL for three consecutive days. Duration of hospitalization was defined as the time between the patients' admission and discharge. Infection was defined as a positive microbial culture. Fever was defined as two oral temperature of 38 1C with one our interval or one oral temperature equal or more than 38.3 1C. The total number of G-CSF injections (300 mg Filgrastim), packed cell and platelet transfusions were recorded.
Statistical analysis
Continuous variables were expressed as mean value ± s.d. Simple descriptive statistics were used for demographic analysis. The distributions of the data were tested by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Nominal data and proportional distributions such as sex and bacterial growth were tested using w 2 and Fisher's exact tests. Numeric data from different groups were tested with unpaired, two-tailed t-test or the MannWhitney U-test, as appropriate. For all the analysis statistical significance was set at Po0.05. The statistical analysis was performed with SPSS vs 17.0 for Windows statistical software package (SPSS Inc., Chicago, IL, USA).
RESULTS
The patient characteristics of the group A were clinically similar to group B. There were no significant differences in gender, age, hematologic malignancy and conditioning regimen between groups (Table 1) .
PN Outcomes PN was started on days þ 6.2 and þ 5.9 in group A and B, respectively. Significant differences were found for total energy expenditure, amino acids, dextrose and lipid by the PN solutions between the two groups as shown in Table 2 . Group A received significantly more energy, protein, dextrose and lipid compared with the group B.The duration of the parenteral support in group A was 7.40±4.69 days (range ¼ 2 À 27 days), and this period for group B was 8.93±3.33 days (range ¼ 2-14 days) with no significant difference.
Nutrition Outcomes
Both regimens failed to maintain body weight during PN administration. Decrease in body weight was significantly greater in group B (Table 4) . Serum concentration variation of total protein and albumin during PN administration, period from PN administration to discharge and period from discontinuation of PN to (Table 7) .
DISCUSSION
In this study, we evaluated the risks and benefits of individualized PN in patients undergoing hematopoietic SCT. The effects of two different types of PN support on nutrition, clinical and hematologic outcomes were evaluated. Our results showed that the individualized PN provide more energy, amino acids, dextrose and lipid compared with the conventional method. Another important finding of this study was less weight loss in group A (individualized PN) comparing to group B (conventional method). Although the duration of fever was the same between two groups, but duration of hospital stay, incidence of infection and platelet engraftment time were significantly lower in group A patients.
Nutrition outcomes During PN administration, group A exhibited a loss of 0.94% and group B 2.72% of body weight. This difference may reflect the fact that both the rate of energy intake and also the total energy intake differed between the two groups. The greater weight loss in group B represents a loss of body weight resulting from a lower total energy intake. 3, 10, 14 Study by Szeluga et al. 10 compared outcomes in hematopoietic SCT patients randomized to TPN or an enteral nutrition. They found that TPN was more effective in maintaining weight or body cell mass compared to enteral nutrition. But, unlike our study, this did not translate into improvements in outcomes such as length of hospital stay and engraftment. Based on the Szeluga study 10 when patients received 40 kcal/kg/day, their body weights increase by 18%, primarily as body fat but those receiving half the calories lose their Meanwhile, weight gain is nearly impossible in hematopoietic SCT patients due to synthesis of catabolic hormones secondary to hematopoietic SCT stress, so the major goals of PN are to minimize starvation effects during the course of transplantation, prevent specific nutrient deficiencies and improve immune and gut-barrier functions. 3, 11, 13, 14 In our study, weight loss is acceptable and our PN method seems to be effective.
Clinical outcomes In our study, group A had a shorter hospital stay. Although the groups were studied at different points in time the other practices were mostly simillar except parenteral nutrition. The same results were shown in study by Horsely et al. 15 It was known that the duration of hospital stay in patients with insufficient nutritional intake was longer than for patients with better nutritional status. So individual assessment of PN requirements is essential to design proper PN to meet the needs of patients. 1, 16 Positive-blood culture was seen more in group B. Sheean et al. 17 and Jeejeebhoy et al.
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concluded that there is a relation between hyperglycemia due to PN and infection. In Sheean et al. study, infection was seen more in hyperglycemic patients (fetal bovine serum 4110 mg/dL) receiving PN than normoglycemic ones. Both studies suggested that strict blood glucose control with insulin could reduce infectious complications. Our study found no significant difference in the rate of infectious complications in the two groups. Dissanaike et al. 19 suggested 'caloric intake' as another variable in the incidence of infection. According to this study, which was conducted on 200 patients in intensive care unit, patients who received 5 kcal/kg/day more energy than other patients were at higher risk of infection. But in our study, the patients who received more energy intake had less infection. This result may be related to differences between intensive care units and BMT patients. Lenssen et al. 20 showed that moderate amounts of i.v. lipid (25-30% of total daily energy) are not associated with an increased incidence of bacterial or fungal infections in patients undergoing BMT and receiving total PN. Similar result was found in our study. It is important to notice that cessation of PN because of infection is not a proper choice. Because such infections are usually treatable bacterial infections, in contrast to fungal and viral infections, which usually occur after engraftment and discontinuation of PN. 6, 21 In addition, chemotherapy, radiotherapy and medicine prescribed to hematopoietic SCT patients may suppress the immune system, which renders hematopoietic SCT patients prone to infection. On the other hand, because of buccal mucositis, esophagitis and enteritis, hematopoietic SCT patients are unable to tolerate oral intake. So termination of PN may result in loss of weight and muscle mass. 6, 21 Hematologic outcomes Our study showed that time to platelet engraftment was shorter in group A than group B. It was revealed in murine studies that engraftment was better with feeding than with fasting. 2 Weisdorf et al. 22 proposed that engraftment is shorter in well-nourished patients. In contrast, some other studies found no beneficial effect of PN on the time to engraftment. 1, 10, 13, 16, 23 As an explanation for this difference, we can mention that in Weisdorf et al. 22 and our study, PN provided B130% of BEE, according to the Harris À Benedict equation, while in the study by Lough et al.
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PN provided 80% of BEE. Cetin et al. 2 proposed that TPN causes delay in platelet and WBC engraftment compared with partial parenteral nutrition. They concluded that an increased rate of infection in the TPN group causes a delay in engraftment. In our study the rate of infection and the time to platelet engraftment were more in group B patients which are similar to Cetin's results. 2 There was no difference in WBC engraftment between groups in our study, which may be because of more G-CSF injections in group B (near significant, P value ¼ 0.06), so it can indirectly shorten the time to WBC engraftment in group B. The amounts of Parenteral nutrition in SCT M Tavakoli-Ardakani et al amino acid, dextrose and lipid administered to two groups were significantly different. One or more of these substances might have negatively affected the duration of platelet engraftment in group B. In Muscaritoli et al. 1,2 study, the duration of platelet engraftment was slightly longer in the lipid-based TPN group than in the glucose-based TPN group, but this difference was not statistically significant. The platelet engraftment might be affected directly or indirectly by changing the metabolism of an inhibitor. However,in our study, engraftment happened earlier in the group who receivied more lipids. Our investigation did not confirm the findings of Muscaritoli et al., study. Judgment on these findings should be based on further studies. According to this study, assessment of more specific nutritional indicators such as prealbumin and nitrogen balance is suggested for explicit evaluation of PN, although in an inflammatory state, the prealbumin (a negative acute phase protein) is very unlikely to provide an accurate assessment of the nutritional status or adequacy of nutrition support, because prealbumin is affected by inflammation and infection in patients. 24 Additionally, obtaining an accurate nitrogen balance study in these patients is problematic due to the common problem of diarrhea, nausea, vomiting and inflammation of the gasterointestinal tract mucosa. These factors would make it very difficult to capture the total protein losses through a urinary urea nitrogen test. We also recommend that it is best to make PN solutions in a clean room, which was not available in Taleghani hospital for our study.
CONCLUSION
According to this study, the use of individualized PN vs conventional PN in hematopoietic SCT patients resulted in decrement of hospital stay, less patient weight loss and infection, rapid platelet engraftment and decrement of packed cell transfusions. So we demonstrated that patients undergo hematopoietic SCT benefit from PN. We conclude that the development of individualized PN for patients undergoing hematopoietic SCT is an important task and its implementation, effectiveness, safety and success, demand the cooperation of a multidisciplinary team (oncologist, clinical pharmacist and clinical dietician).
